溶瘤病毒疗法：打造“生物战士” 精准攻击肿瘤

Core Viewpoint - The innovative intracranial injection method for oncolytic virus therapy enhances the convenience of treating brain tumors, demonstrating safety and efficacy in treating pediatric diffuse intrinsic pontine glioma (DIPG) with the new oncolytic virus Ad-TD-nsIL12 [1][6] Group 1: Oncolytic Virus Therapy - Oncolytic virus therapy is emerging as a disruptive new strategy for cancer treatment, with the potential to revolutionize clinical practices [2] - This therapy selectively infects and destroys tumor cells while activating the immune system, providing a dual mechanism of action against tumors [3][4] - The engineered oncolytic virus is designed to replicate specifically within tumor cells, minimizing harm to normal cells and enhancing therapeutic efficacy [5] Group 2: Mechanism and Design - The oncolytic virus used in the study is based on human adenovirus type 5 (Ad5) and has undergone genetic modifications to improve targeting and reduce toxicity [5] - Key genetic deletions enhance the virus's ability to kill tumor cells and improve the presentation of tumor-specific antigens to the immune system [5] - The introduction of non-secretory interleukin-12 (IL-12) maintains normal levels in the bloodstream, promoting systemic anti-tumor immunity while avoiding side effects from elevated IL-12 levels [5] Group 3: Clinical Trials and Results - Clinical trials have confirmed the safety of the oncolytic virus Ad-TD-nsIL12, with significant preclinical and clinical evidence supporting its effectiveness [6] - Over 200 oncolytic virus-related clinical trials are currently underway globally, with a significant portion originating from China [7] - Notable results from CG Oncology's phase 3 trial showed complete tumor disappearance in 82 out of 110 patients treated with their oncolytic virus therapy [7] Group 4: Future Directions - To accelerate the clinical translation of oncolytic virus therapy, collaboration between basic and clinical research is essential, along with enhanced communication among researchers and clinicians [7] - Future studies will explore the combination of oncolytic virus therapy with surgery, radiotherapy, and antibody treatments to address the heterogeneity of malignant tumors [8]